NL-OMON20248尚未招募不适用
INTERVENTION STUDY FOR THE RELIEF OF ORAL DRYNESS – NOVOSPRAY
Academic Centre for Dentistry Amsterdam (ACTA)0 个研究点目标入组 35 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female, over 18 years of age, and capable of providing their written informed consent.
- •An unstimulated whole mouth salivary flow < 0.20 ml/min [8].
- •Demonstrated moderate to severe level of dry mouth at screening, as indicated by an XI-score of 25 or higher
- •Diagnosis of Sjögren's syndrome.
- •Access to internet.
排除标准
- •Patients currently using a potassium-sparing diuretic antihypertensive drug that contains amiloride; spironolactone (e.g.,Aldactone, Novo-Spiroton, Spiractin, Spirtone, Verospiron or Berlactone); triamterene (e.g., Dyrenium); or plerenone (e.g., Inspra). Chronic use of antihistamines will be permitted if started at least 30 days before the start of the trial, and a stable dose is maintained throughout the trial.
- •Patients who started using systemic cholinergic secretagogues or tricyclic antidepressant drugs within 12 weeks before screening, patients who are not on a stable dosing regimen for at least 14 days prior to the screening visit, or patients who are unable to maintain stable dosing throughout the study.
- •Females who are pregnant or trying to become pregnant, or are nursing.
- •Patients showing evidence of a significant active or ongoing oral infection or other oral conditions (eg, lichen planus) that, in the opinion of the Investigator, might affect the safety of the subject or be exacerbated during study participation.
- •Patients suffering from acute infections of the salivary glands.
- •Patients with a present history of any clinically significant and uncontrolled neurologic, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, or hematological disorder or disease, or any other major disorder or disease, in the opinion of the Investigator.
- •Patients consuming more than 2 alcoholic drinks per day or with a significant history of alcoholism or drug/chemical abuse within the past 12 months.
- •Patients who have received an investigational drug within the past 30 days.
- •Patients with a history of allergy to chicken egg proteins or food preservatives
- •Patients having an unstimulated whole mouth salivary flow > 0.20 ml/min.
研究者
相似试验
已完成
不适用
INTERVENTION STUDY FOR THE RELIEF OF ORAL DRYNESS * NOVOSPRAYxerostomiaNL-OMON48000Academisch Centrum Tandheelkunde Amsterdam (ACTA)35
已完成
不适用
Intervention study of oral dryness - Armor.xerostomiaxerostomiedry mouth sensationNL-OMON40736VU Medical Centre66
尚未招募
1 期
Efficacy of Oral Intervention of Rasona Ksheerpak In Aartavkshay W.S.R. to Secondary Hypomenorrhea.CTRI/2021/08/036018HonShri Annasaheb Dange Ayurved Medical College And Post Graduate and Research Center Ashta
进行中（未招募）
不适用
Investigating the influence of an oral rinse intervention, containing a taste stimuli, on participants taste perception/sensitivity.ACTRN12619000713190Deakin University, School of Exercise and Nutrition Sciences, Centre for Advanced Sensory Science.44
已完成
2 期
The feasibility study of Oral rehydration therapy for Short hydration in chemotherapy with cisplatin plus gemcitabine for biliary tract cancerbiliary tract cancerJPRN-UMIN000010695Kansai Hepatobiliary Oncology Group (KHBO)50